Objective:
To determine the predictive value of OCT-detected retinal biomarkers at baseline for switching therapies in patients with diabetic macular edema (DME), specifically focusing on how these biomarkers can indicate potential treatment failure.
Key Findings:
- 76% of eyes required a switch from anti-VEGF therapy to DEX-i due to suboptimal response.
- Patients requiring a switch had worse baseline parameters: mean age 69 years, initial BCVA of 0.3, and higher CRT of 492.3 µm.
- Presence of two OCT markers (SRF, HCW, VMI) raised odds of treatment failure by a factor of 49, indicating a significant risk for these patients.
- All three markers correlated with near-certain failure of anti-VEGF therapy, with an odds ratio suggesting extreme risk.
Interpretation:
Early identification of poor responders to anti-VEGF therapy could justify an earlier switch to steroids, particularly in patients with high CRT or specific OCT abnormalities, potentially improving patient outcomes.
Limitations:
- Study was retrospective, which may introduce bias.
- Variability in switch criteria among centers could affect the generalizability of the findings.
Conclusion:
A multicentric study with a larger sample size is needed to confirm findings and improve treatment efficiency for patients with DME, particularly focusing on the predictive value of OCT biomarkers.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
